PuSH - Publication Server of Helmholtz Zentrum München

Hutter, G. ; Rieken, M.* ; Pastore, A. ; Weigert, O. ; Zimmermann, Y. ; Weinkauf, M. ; Hiddemann, W.* ; Dreyling, M.

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.

Ann. Hematol. 91, 847-856 (2012)
DOI PMC
Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
Single-agent bortezomib, a potent, selective, and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the MCL patients; however, complete remission rates are low and duration of response proved to be relatively short. These limitations may be overcome by combining proteasome inhibition with conventional chemotherapy. Rational combination treatment and schedules require profound knowledge of underlying molecular mechanisms. Here we show that single-agent bortezomib treatment of MCL cell lines leads to G2/M arrest and induction of apoptosis accompanied by downregulation of EIF4E and CCND1 mRNA but upregulation of p15(INK4B) and p21 mRNA. We further present synergistic efficacy of bortezomib combined with cytarabine in MCL cell lines. Interestingly this sequence-dependent synergistic effect was seen almost exclusively in combination with AraC, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Mcl ; Bortezomib ; Arac ; Apoptosis ; Cell Cycle Arrest; PHASE-I TRIAL; MULTIPLE-MYELOMA; SINGLE-AGENT; HEMATOLOGIC MALIGNANCIES; TRANSLATION INITIATION; LEUKEMIA CELLS; ACTIVATION; SENSITIVITY; PROTEIN; CANCER
ISSN (print) / ISBN 0939-5555
e-ISSN 1432-0584
Journal Annals of Hematology
Quellenangaben Volume: 91, Issue: 6, Pages: 847-856 Article Number: , Supplement: ,
Publisher Springer
Reviewing status Peer reviewed
Institute(s) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)